The UK Government’s Department of Health and Social Care has announced an additional £20 million funding to CEPI to further our mission to advance vaccines against epidemic threats. The funding comes amid the rapid global spread of the outbreak of a novel coronavirus, 2019-nCoV.
The funding was announced by UK Health Secretary Matt Hancock to support our work to develop a wide range of vaccine candidates and platform technologies against emerging infectious diseases. This includes our priority pathogens – Lassa fever, MERS, Nipah, Chikungunya, Rift Valley fever, Ebola, and Disease X – as well as our newly developed programmes to advance vaccines against the novel coronavirus, 2019-nCoV.
UK Secretary of State for Health and Social Care
CEPI has moved with great urgency and in coordination with the World Health Organization (WHO)—who is leading the development of a coordinated international response—to develop vaccines against the novel coronavirus, 2019-nCoV. The vaccine development programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance novel coronavirus vaccine candidates into clinical testing as quickly as possible.
Chief Executive Officer, CEPI
The UK DHSC first pledged £10 million funding to CEPI to support our work in January 2019.
CEPI’s investors include the governments of Norway, Germany, Japan, Canada, Australia, Belgium and the UK, as well as the Bill & Melinda Gates Foundation, Wellcome Trust and the European Commission.
Further information on today’s announcement is available here.